Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast

Rachael Natrajan, Paul M. Wilkerson, Caterina Marchiò, Salvatore Piscuoglio, Charlotte K Y Ng, Patty Wai, Maryou B. Lambros, Eleftherios P. Samartzis, Konstantin J. Dedes, Jessica Frankum, Ilirjana Bajrami, Alicja Kopec, Alan Mackay, Roger A'Hern, Kerry Fenwick, Iwanka Kozarewa, Jarle Hakas, Costas Mitsopoulos, David Hardisson, Christopher J. LordChandan Kumar-Sinha, Alan Ashworth, Britta Weigelt, Anna Sapino, Arul M. Chinnaiyan, Christopher A. Maher, Jorge S. Reis-Filho

Research output: Contribution to journalArticlepeer-review

Abstract

Micropapillary carcinoma (MPC) is a rare histological special type of breast cancer, characterized by an aggressive clinical behaviour and a pattern of copy number aberrations (CNAs) distinct from that of grade- and oestrogen receptor (ER)-matched invasive carcinomas of no special type (IC-NSTs). The aims of this study were to determine whether MPCs are underpinned by a recurrent fusion gene(s) or mutations in 273 genes recurrently mutated in breast cancer. Sixteen MPCs were subjected to microarray-based comparative genomic hybridization (aCGH) analysis and Sequenom OncoCarta mutation analysis. Eight and five MPCs were subjected to targeted capture and RNA sequencing, respectively. aCGH analysis confirmed our previous observations about the repertoire of CNAs of MPCs. Sequencing analysis revealed a spectrum of mutations similar to those of luminal B IC-NSTs, and recurrent mutations affecting mitogen-activated protein kinase family genes and NBPF10. RNA-sequencing analysis identified 17 high-confidence fusion genes, eight of which were validated and two of which were in-frame. No recurrent fusions were identified in an independent series of MPCs and IC-NSTs. Forced expression of in-frame fusion genes (SLC2A1-FAF1 and BCAS4-AURKA) resulted in increased viability of breast cancer cells. In addition, genomic disruption of CDK12 caused by out-of-frame rearrangements was found in one MPC and in 13% of HER2-positive breast cancers, identified through a re-analysis of publicly available massively parallel sequencing data. In vitro analyses revealed that CDK12 gene disruption results in sensitivity to PARP inhibition, and forced expression of wild-type CDK12 in a CDK12-null cell line model resulted in relative resistance to PARP inhibition. Our findings demonstrate that MPCs are neither defined by highly recurrent mutations in the 273 genes tested, nor underpinned by a recurrent fusion gene. Although seemingly private genetic events, some of the fusion transcripts found in MPCs may play a role in maintenance of a malignant phenotype and potentially offer therapeutic opportunities.

Original languageEnglish
Pages (from-to)553-565
Number of pages13
JournalJournal of Pathology
Volume232
Issue number5
DOIs
Publication statusPublished - 2014

Keywords

  • breast cancer
  • CDK12
  • fusion transcripts
  • micropapillary
  • PARP inhibitors
  • RNA sequencing
  • somatic mutation profiling

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast'. Together they form a unique fingerprint.

Cite this